Urologix, Inc. (OTCPK:ULGX) will continue reviewing various strategic alternatives available to the Company, including the sale of the Company or its assets, partnering or other collaboration agreements, or a merger, reverse merger or other strategic transaction.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% |
|
-.--% | -.--% |
2016 | A unknown buyer acquired substantially all of the operating assets of Urologix, Inc. | CI |
2015 | Urologix Conducting A Strategic Review | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 2.13K | |
+5.51% | 212B | |
+9.92% | 188B | |
+31.30% | 157B | |
+33.53% | 114B | |
+3.46% | 64.01B | |
+1.51% | 48.83B | |
-4.15% | 39.3B | |
+1.84% | 35.97B | |
+7.74% | 27B |
- Stock Market
- Equities
- ULGX Stock
- News Urologix, Inc.
- Urologix Conducting A Strategic Review